NCT03534635View on ClinicalTrials.gov

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting
Interventions
DRUG

Pembrolizumab

Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.

DRUG

Pembrolizumab - additional treatment

Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).

Trial Locations (1)

1011

CHUV, Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT03534635 - Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | Biotech Hunter | Biotech Hunter